Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The order environment remained favourable, orders for financial IT were strong, sales of medical and healthcare products and security products grew, and system development related to new technologies such as DX and AI grew significantly. Although selling, general and administrative expenses and other costs increased in line with growth investments, operating profit rose due to the effect of higher revenue and other factors.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥62,330 million (YoY +10.1%) |
| Operating profit | ¥9,063 million (YoY +10.0%) |
| Ordinary income | ¥9,216 million (YoY +10.3%) |
| Profit attributable to owners of the parent | ¥5,778 million (YoY +7.6%) |
| Net income per share | ¥76.40 |
| Equity ratio | End of the current fiscal period 73 / End of previous period 75.7 |
| Total assets | ¥96,605 million |
| Net assets | ¥71,554 million |
| Cash flows from operating activities | ¥9,063 million |
| Cash flows from investing activities | ¥-4,699 million |
| Cash flows from financing activities | ¥-9,150 million |
| Cash and cash equivalents at end of period | ¥27,697 million |
| Full-year earnings forecast | Net Sales ¥128,000 million (YoY +8.6%) / Operating profit ¥20,100 million (YoY +5.4%) / Ordinary income ¥20,400 million (YoY +5.6%) / Net income ¥13,300 million (YoY +2.2%) |
| Annual Dividend Forecast | ¥96 → ¥100 |
| Segment revenue | Systems development business ¥53,621 million (YoY +9.5%) / Solutions Business ¥9,138 million (YoY +14.7%) |
| Segment profit | Systems development business ¥9,097 million (YoY +8.6%) / Solutions Business ¥430 million (YoY +187.4%) |
| Depreciation and amortization | ¥666 million |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Name Gain on sale of non-current assets / Amount ¥0 million / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Additions: 0 companies; removals: 0 companies (no significant changes) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 86,000,000 |
| Treasury Shares at Period-End | 10,680,935 |
| Factors Behind Changes in Business Performance | The order environment remained favourable, orders for financial IT were strong, sales of medical and healthcare products and security products grew, and system development related to new technologies such as DX and AI grew significantly. Although selling, general and administrative expenses and other costs increased in line with growth investments, operating profit rose due to the effect of higher revenue and other factors. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A favourable order environment, strong orders for financial IT, growth in sales of medical and healthcare products and security products, and growth in system development related to new technologies such as DX and AI. Although selling, general and administrative expenses and other costs increased in line with growth investments, operating profit rose due to the effect of higher revenue and other factors.